Indian regulators ordered Sun Pharmaceutical Industries to halt manufacturing, selling, and distributing ophthalmic products at its Assam plant due to quality management failures.
The Central Drugs Standard Control Organisation and Assam drug authorities issued the shutdown order on August 20 following a joint inspection and a voluntary recall of 332 batches.
Sun Pharma reported a 36% plunge in second-quarter profit on Friday due to exceptional charges, with adjusted net profit standing at ₹3,162 crore.